Biased agonists of GPR84 and insights into biological control

GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reporte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2024-05, Vol.181 (10), p.1509-1523
Hauptverfasser: Luscombe, Vincent B., Wang, Pinqi, Russell, Angela J., Greaves, David R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1523
container_issue 10
container_start_page 1509
container_title British journal of pharmacology
container_volume 181
creator Luscombe, Vincent B.
Wang, Pinqi
Russell, Angela J.
Greaves, David R.
description GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reported ligands for this receptor were medium chain fatty acids with chain lengths between 9 and 12 carbons. Subsequently, a series of synthetic agonists that signal via the GPR84 receptor were identified. Radioligand binding assays and molecular modelling with site‐directed mutagenesis suggest the presence of three ligand binding sites on the receptor, but the physiological agonist(s) of the receptor remain unidentified. Here, we review the effects of GPR84 agonists on innate immune cells following a series of chemical discoveries since 2001. The development of highly biased agonists has helped to probe receptor function in vitro, and the remaining challenge is to follow the effects of biased signalling to the physiological functions of innate immune cell types. LINKED ARTICLES This article is part of a themed issue GPR84 Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.10/issuetoc
doi_str_mv 10.1111/bph.16310
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2906772030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3039640895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3880-f06f81c57192c359db331475744c103e8b1ad4b37fc6a74255691b3feb00c1b43</originalsourceid><addsrcrecordid>eNp1kMFLwzAUxoMobk4P_gNS8KKHbi9L2qQHD27oJgwcoueQpOmW0TWzaZH990Y7PQi-y4P3_fj43ofQJYYhDjNSu_UQpwTDEepjytI4IRwfoz4AsBhjznvozPsNQBBZcop6QaacjaGP7iZWepNHcuUq6xsfuSKaLV84jWSVR7bydrUOV1s1LlLWlW5ltSwj7aqmduU5Oilk6c3FYQ_Q2-PD63QeL55nT9P7RawJ5xAXkBYc64ThbKxJkuWKkBAlYZRqDMRwhWVOFWGFTiWj4yRJM6xIYRSAxoqSAbrpfHe1e2-Nb8TWem3KUlbGtV6MM0hZ-IdAQK__oBvX1lVIJ4KapRR4lgTqtqN07byvTSF2td3Kei8wiK9ORehUfHca2KuDY6u2Jv8lf0oMwKgDPmxp9v87icly3ll-Ajj1fPY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039640895</pqid></control><display><type>article</type><title>Biased agonists of GPR84 and insights into biological control</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Luscombe, Vincent B. ; Wang, Pinqi ; Russell, Angela J. ; Greaves, David R.</creator><creatorcontrib>Luscombe, Vincent B. ; Wang, Pinqi ; Russell, Angela J. ; Greaves, David R.</creatorcontrib><description>GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reported ligands for this receptor were medium chain fatty acids with chain lengths between 9 and 12 carbons. Subsequently, a series of synthetic agonists that signal via the GPR84 receptor were identified. Radioligand binding assays and molecular modelling with site‐directed mutagenesis suggest the presence of three ligand binding sites on the receptor, but the physiological agonist(s) of the receptor remain unidentified. Here, we review the effects of GPR84 agonists on innate immune cells following a series of chemical discoveries since 2001. The development of highly biased agonists has helped to probe receptor function in vitro, and the remaining challenge is to follow the effects of biased signalling to the physiological functions of innate immune cell types. LINKED ARTICLES This article is part of a themed issue GPR84 Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.10/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.16310</identifier><identifier>PMID: 38148720</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Agonists ; Biological control ; GPCR biased agonism ; GPCRs and drug development ; GPR84 ; Leukocytes (neutrophilic) ; macrophage biology ; Macrophages ; Molecular modelling ; mRNA ; Mutagenesis ; orphan GPCRs ; Physiology</subject><ispartof>British journal of pharmacology, 2024-05, Vol.181 (10), p.1509-1523</ispartof><rights>2024 The Authors. published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</rights><rights>This article is protected by copyright. All rights reserved.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3880-f06f81c57192c359db331475744c103e8b1ad4b37fc6a74255691b3feb00c1b43</citedby><cites>FETCH-LOGICAL-c3880-f06f81c57192c359db331475744c103e8b1ad4b37fc6a74255691b3feb00c1b43</cites><orcidid>0000-0002-2886-4017 ; 0009-0007-1160-1206 ; 0000-0003-2856-9410 ; 0000-0003-3610-9369</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbph.16310$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbph.16310$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38148720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luscombe, Vincent B.</creatorcontrib><creatorcontrib>Wang, Pinqi</creatorcontrib><creatorcontrib>Russell, Angela J.</creatorcontrib><creatorcontrib>Greaves, David R.</creatorcontrib><title>Biased agonists of GPR84 and insights into biological control</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reported ligands for this receptor were medium chain fatty acids with chain lengths between 9 and 12 carbons. Subsequently, a series of synthetic agonists that signal via the GPR84 receptor were identified. Radioligand binding assays and molecular modelling with site‐directed mutagenesis suggest the presence of three ligand binding sites on the receptor, but the physiological agonist(s) of the receptor remain unidentified. Here, we review the effects of GPR84 agonists on innate immune cells following a series of chemical discoveries since 2001. The development of highly biased agonists has helped to probe receptor function in vitro, and the remaining challenge is to follow the effects of biased signalling to the physiological functions of innate immune cell types. LINKED ARTICLES This article is part of a themed issue GPR84 Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.10/issuetoc</description><subject>Agonists</subject><subject>Biological control</subject><subject>GPCR biased agonism</subject><subject>GPCRs and drug development</subject><subject>GPR84</subject><subject>Leukocytes (neutrophilic)</subject><subject>macrophage biology</subject><subject>Macrophages</subject><subject>Molecular modelling</subject><subject>mRNA</subject><subject>Mutagenesis</subject><subject>orphan GPCRs</subject><subject>Physiology</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kMFLwzAUxoMobk4P_gNS8KKHbi9L2qQHD27oJgwcoueQpOmW0TWzaZH990Y7PQi-y4P3_fj43ofQJYYhDjNSu_UQpwTDEepjytI4IRwfoz4AsBhjznvozPsNQBBZcop6QaacjaGP7iZWepNHcuUq6xsfuSKaLV84jWSVR7bydrUOV1s1LlLWlW5ltSwj7aqmduU5Oilk6c3FYQ_Q2-PD63QeL55nT9P7RawJ5xAXkBYc64ThbKxJkuWKkBAlYZRqDMRwhWVOFWGFTiWj4yRJM6xIYRSAxoqSAbrpfHe1e2-Nb8TWem3KUlbGtV6MM0hZ-IdAQK__oBvX1lVIJ4KapRR4lgTqtqN07byvTSF2td3Kei8wiK9ORehUfHca2KuDY6u2Jv8lf0oMwKgDPmxp9v87icly3ll-Ajj1fPY</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Luscombe, Vincent B.</creator><creator>Wang, Pinqi</creator><creator>Russell, Angela J.</creator><creator>Greaves, David R.</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2886-4017</orcidid><orcidid>https://orcid.org/0009-0007-1160-1206</orcidid><orcidid>https://orcid.org/0000-0003-2856-9410</orcidid><orcidid>https://orcid.org/0000-0003-3610-9369</orcidid></search><sort><creationdate>202405</creationdate><title>Biased agonists of GPR84 and insights into biological control</title><author>Luscombe, Vincent B. ; Wang, Pinqi ; Russell, Angela J. ; Greaves, David R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3880-f06f81c57192c359db331475744c103e8b1ad4b37fc6a74255691b3feb00c1b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Agonists</topic><topic>Biological control</topic><topic>GPCR biased agonism</topic><topic>GPCRs and drug development</topic><topic>GPR84</topic><topic>Leukocytes (neutrophilic)</topic><topic>macrophage biology</topic><topic>Macrophages</topic><topic>Molecular modelling</topic><topic>mRNA</topic><topic>Mutagenesis</topic><topic>orphan GPCRs</topic><topic>Physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luscombe, Vincent B.</creatorcontrib><creatorcontrib>Wang, Pinqi</creatorcontrib><creatorcontrib>Russell, Angela J.</creatorcontrib><creatorcontrib>Greaves, David R.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luscombe, Vincent B.</au><au>Wang, Pinqi</au><au>Russell, Angela J.</au><au>Greaves, David R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biased agonists of GPR84 and insights into biological control</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2024-05</date><risdate>2024</risdate><volume>181</volume><issue>10</issue><spage>1509</spage><epage>1523</epage><pages>1509-1523</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>GPR84 was first identified as an open reading frame encoding an orphan Class A G protein coupled receptor in 2001. Gpr84 mRNA is expressed in a limited number of cell types with the highest levels of expression being in innate immune cells, M1 polarised macrophages and neutrophils. The first reported ligands for this receptor were medium chain fatty acids with chain lengths between 9 and 12 carbons. Subsequently, a series of synthetic agonists that signal via the GPR84 receptor were identified. Radioligand binding assays and molecular modelling with site‐directed mutagenesis suggest the presence of three ligand binding sites on the receptor, but the physiological agonist(s) of the receptor remain unidentified. Here, we review the effects of GPR84 agonists on innate immune cells following a series of chemical discoveries since 2001. The development of highly biased agonists has helped to probe receptor function in vitro, and the remaining challenge is to follow the effects of biased signalling to the physiological functions of innate immune cell types. LINKED ARTICLES This article is part of a themed issue GPR84 Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.10/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>38148720</pmid><doi>10.1111/bph.16310</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-2886-4017</orcidid><orcidid>https://orcid.org/0009-0007-1160-1206</orcidid><orcidid>https://orcid.org/0000-0003-2856-9410</orcidid><orcidid>https://orcid.org/0000-0003-3610-9369</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2024-05, Vol.181 (10), p.1509-1523
issn 0007-1188
1476-5381
language eng
recordid cdi_proquest_miscellaneous_2906772030
source Wiley Online Library Journals Frontfile Complete
subjects Agonists
Biological control
GPCR biased agonism
GPCRs and drug development
GPR84
Leukocytes (neutrophilic)
macrophage biology
Macrophages
Molecular modelling
mRNA
Mutagenesis
orphan GPCRs
Physiology
title Biased agonists of GPR84 and insights into biological control
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T13%3A38%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biased%20agonists%20of%20GPR84%20and%20insights%20into%20biological%20control&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Luscombe,%20Vincent%20B.&rft.date=2024-05&rft.volume=181&rft.issue=10&rft.spage=1509&rft.epage=1523&rft.pages=1509-1523&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.16310&rft_dat=%3Cproquest_cross%3E3039640895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039640895&rft_id=info:pmid/38148720&rfr_iscdi=true